An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.

Saved in:
Bibliographic Details
Title: An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.
Authors: Chan S; AbbVie Redwood City, Redwood City, CA, USA., Belmar N; AbbVie Redwood City, Redwood City, CA, USA., Ho S; AbbVie Redwood City, Redwood City, CA, USA., Rogers B; AbbVie Redwood City, Redwood City, CA, USA., Stickler M; Calico Labs, South San Francisco, CA, USA., Graham M; AbbVie Redwood City, Redwood City, CA, USA., Lee E; AbbVie Redwood City, Redwood City, CA, USA., Tran N; AbbVie Redwood City, Redwood City, CA, USA., Zhang D; AbbVie Redwood City, Redwood City, CA, USA., Gupta P; Seattle Genetics, South San Francisco, CA, USA., Sho M; AbbVie Redwood City, Redwood City, CA, USA., MacDonough T; Atomwise, San Francisco, CA, USA., Woolley A; Bristol Myers Squibb, Redwood City, CA, USA., Kim H; Bolt Biotherapeutics, Inc., Redwood City, CA, USA., Zhang H; Sanofi, Cambridge, MA, USA., Liu W; AbbVie Redwood City, Redwood City, CA, USA., Zheng P; AbbVie Redwood City, Redwood City, CA, USA., Dezso Z; AbbVie Redwood City, Redwood City, CA, USA., Halliwill K; AbbVie Redwood City, Redwood City, CA, USA., Ceccarelli M; University of Naples Federico II, Naples, Italy., Rhodes S; AbbVie Redwood City, Redwood City, CA, USA., Thakur A; AbbVie Redwood City, Redwood City, CA, USA., Forsyth CM; AbbVie Redwood City, Redwood City, CA, USA., Xiong M; AbbVie Redwood City, Redwood City, CA, USA., Tan SS; AbbVie Redwood City, Redwood City, CA, USA., Iyer R; AbbVie, Inc., North Chicago, IL, USA., Lake M; AbbVie, Inc., North Chicago, IL, USA., Digiammarino E; AbbVie, Inc., North Chicago, IL, USA., Zhou L; AbbVie Bioresearch Center, Worcester, MA, USA., Bigelow L; AbbVie, Inc., North Chicago, IL, USA., Longenecker K; AbbVie, Inc., North Chicago, IL, USA., Judge RA; AbbVie, Inc., North Chicago, IL, USA., Liu C; AbbVie Bioresearch Center, Worcester, MA, USA., Trumble M; AbbVie Bioresearch Center, Worcester, MA, USA., Remis JP; Former Department of Molecular Biosciences, Northwestern University, Evanston, IL, USA.; California Institute for Quantitative Biosciences, University of California, Berkeley, CA, USA., Fox M; AbbVie Redwood City, Redwood City, CA, USA., Cairns B; Oxford Biotherapeutics, San Jose, CA, USA., Akamatsu Y; AbbVie Redwood City, Redwood City, CA, USA., Hollenbaugh D; Good Therapeutics, Inc., Seattle, WA, USA., Harding F; Calico Labs, South San Francisco, CA, USA., Alvarez HM; AbbVie Redwood City, Redwood City, CA, USA. hamsell.alvarezjares@abbvie.com.
Source: Nature cancer [Nat Cancer] 2022 Mar; Vol. 3 (3), pp. 337-354. Date of Electronic Publication: 2022 Mar 07.
Publication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2662-1347
DOI:10.1038/s43018-022-00334-9